S85 Clinical characteristics associated with mucus plugging in severe eosinophilic asthma and the effectiveness of benralizumab treatment

Abstract

severe asthma exacerbations (AER) during QUEST (Weeks 0– 52) and TRAVERSE (Weeks 0–48 and Weeks 48–96) and the mean change from QUEST baseline in pre-bronchodilator FEV1 in QUEST over the QUEST and TRAVERSE studies. Results The unadjusted AER in dupilumab-treated patients was low during QUEST, with progressive reductions observed during the treatment period of 96 weeks in TRAVERSE and a majority of patients experiencing no exacerbations (figure 1A). In the placebo/dupilumab group of patients, the unadjusted AER decreased significantly during TRAVERSE compared with QUEST and was similar to the AER in dupilumab/dupilumab patients. Clinically meaningful improvements in pre-bronchodilator FEV1 were observed at Week 52 of QUEST in dupilumab/dupilumab patients, which were sustained with no apparent loss of treatment effect at Weeks 48 and 96 of TRAVERSE (figure 1B). Large improvements in pre-bronchodilator FEV1 were observed in placebo/dupilumab patients upon initiation of dupilumab, which were sustained throughout the TRAVERSE treatment period. Conclusions Dupilumab demonstrated sustained efficacy in reducing severe asthma exacerbations and improving lung function in patients with moderate-to-severe asthma who completed 96 weeks of treatment.